Showing 31-40 of 346 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| β Cell Mitochondrial Health as a Driver and Indicator of Immune Activation in Type 1 Diabetes | Trustees of Indiana University | Carmella Evans-Molina | Cures | 01-March-2026 to 28-February-2029 | $748.179,00 |
| Platforms for Cross-Therapeutic Profiling and Mechanistic Studies of Immune-Modifying Therapies in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Dan Campbell | Cures | 01-March-2026 to 28-February-2029 | $1.045.621,50 |
| Interferons and the Integrated Stress Response: Converging Pathways in β Cell Dysfunction in Type 1 Diabetes | The University of Chicago | Charanya Muralidharan | Cures | 01-March-2026 to 28-February-2029 | $285.000,00 |
| B cell-Treg interactions in immune therapy for T1D | Vanderbilt University Medical Center (VUMC) | Daniel Moore | Cures | 01-March-2026 to 28-February-2029 | $660.000,00 |
| Type I Interferons and B Cell Metabolism as Drivers of Type 1 Diabetes | Trustees of Indiana University | Jamie Felton | Cures | 01-February-2026 to 31-January-2029 | $682.534,00 |
| Controlling cytoarchitecture and function in novel stem-cell-based implants intended for T1D therapy | Mayo Clinic | Quinn Peterson | Cures | 01-February-2026 to 31-January-2028 | $600.000,00 |
| Overcoming Production Barriers to Stem Cell-Islet Therapies Through Scalable Technologies | Washington University | Jeffrey Millman | Cures | 01-March-2026 to 29-February-2028 | $550.000,00 |
| Immune-cell targeted TLR7 antagonist to halt the attack on beta−cells in the context of Type 1 Diabetes | Tezcat Bio | Craig Ramirez | Cures | 15-January-2026 to 31-December-2026 | $100.000,00 |
| Stromal Cell Targeted Tolerogenic mRNA Therapy for T1D | Endotope Biosciences | Raymond Liang | Cures | 15-December-2025 to — | $550.417,82 |
| Process development for adipose tissue implantation of immune evasive ES-derived islet-like cells | University of Wisconsin-Madison (Board of Regents University of Wisconsin System) | Jacques Galipeau | Cures | 01-January-2026 to 31-December-2027 | $628.883,28 |